Population pharmacokinetics and exposure–response relationship of the antituberculosis drug BTZ-043

We characterized the population PK/PD of BTZ-043 in trial participants with pulmonary TB. An exposure-response relationship was only apparent for the first 2 days on treatment, indicating the need for further dose-finding studies.

Authors

Institutions

Publication Details

Journal
Journal of Antimicrobial Chemotherapy
Published
2025-03-28
DOI
https://doi.org/10.1093/jac/dkaf076
Citations
3
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
4.19

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Population pharmacokinetics and exposure–response relationship of the antituberculosis drug BTZ-043

Rodney Dawson, Timothy D. McHugh, Kim Narunsky, Elin M. Svensson et al.
3 citations
Journal of Antimicrobial Chemotherapy
Tuberculosis Research and Epidemiology
4.19
article

Population pharmacokinetics and exposure–response relationship of the antituberculosis drug BTZ-043

Rodney Dawson, Timothy D. McHugh, Kim Narunsky, Elin M. Svensson, Patrick P. J. Phillips, Julia Dreisbach, Simon E. Koele, Michael Höelscher, Letícia Muraro Wildner, Lindsey H. M. te Brake, Veronique de Jager, Rob E. Aarnoutse, Norbert Heinrich, Petra Gross-Demel, Andreas H. Diacon
article en
3 citations

Abstract

We characterized the population PK/PD of BTZ-043 in trial participants with pulmonary TB. An exposure-response relationship was only apparent for the first 2 days on treatment, indicating the need for further dose-finding studies.

Journal of Antimicrobial ChemotherapyVol. 80(5)
Uppsala University (SE), Radboud University Nijmegen (NL), University of Cape Town (ZA), University of California, San Francisco (US), Center for Environmental Health (US), University Medical Center (US), Radboud University Medical Center (NL), Helmholtz Zentrum München (DE), Task Applied Science (ZA), Lung Institute (US), Fraunhofer Institute for Translational Medicine and Pharmacology (DE), German Center for Infection Research (DE), South African Tuberculosis Vaccine Initiative (ZA), University College London (GB), Ludwig-Maximilians-Universität München (DE)
Deutsches Zentrum für Infektionsforschung, Bundesministerium für Bildung und Forschung, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Bayerisches Staatsministerium für Wissenschaft und Kunst, European and Developing Countries Clinical Trials Partnership
Openalex Percentile: Top 7%
Tuberculosis Research and Epidemiology
4.19
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.